ClinicalTrials.gg
CompletedNCT01860638Updated Apr 30, 2018

A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma

A Phase 2 interventional study of Bevacizumab and Lomustine in Glioblastoma, sponsored by Hoffmann-La Roche. Completed at 64 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-30.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
296
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 97 studies testing bevacizumab in Glioblastoma — 8 open to participants now, 13 under way, 1 of them phase 3. Bevacizumab · Glioblastoma.

Enrollment
5th of 97
296 · median 48
Started
2013
with 6 others
Phase 2
57 of 97
3 open now
Registered
59th of 97
by date
Lead sponsor
4 of 97
Hoffmann-La Roche

Among the 97 studies testing bevacizumab in Glioblastoma, this one is the 5th largest by enrollment, is one of 7 that started in 2013, is one of 57 in phase 2, and was the 59th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

8 of the 97 studies testing bevacizumab in Glioblastoma are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies testing bevacizumab in Glioblastoma, or all of them as a file.
02

Study summary

This multicenter, double-blind, placebo-controlled, randomized study will evaluate the efficacy and safety of the addition of bevacizumab treatment to lomustine (in 2nd-line [2L] treatment) and SOC (in 3rd-line [3L] and subsequent lines of treatment) following first-line disease progression (PD1) in participants with newly diagnosed glioblastoma. All enrolled participants will receive 1L treatment with radiotherapy, temozolomide, and bevacizumab. At PD1, eligible participants will be randomized (1:1) to receive 2L treatment with either bevacizumab plus lomustine or placebo plus lomustine. After second-line disease progression (PD2), participants will receive 3L treatment and will continue blinded bevacizumab or placebo with the addition of an SOC agent. Following third-line disease progression (PD3), participants will receive subsequent lines of treatment and will either continue blinded bevacizumab or placebo (at the discretion of the investigator), or switch to open-label bevacizumab (at the choice of the participant).

03

Conditions studied

  • Glioblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed, confirmed glioblastoma not previously treated with chemotherapy or radiotherapy
  • If female and not (less than [\<] 12 months of amenorrhea) or surgically sterile, must agree to use a highly effective method during the treatment period and for at least 6 months after the last dose of study drug
  • performance status (KPS) greater than or equal to (>/=) 60
  • Mandatory tissue collection during pre-study surgery or for confirmation of the diagnosis and pathology
  • Craniotomy or intracranial biopsy site must be adequately healed. Study treatment should be initiated > 28 days following the last surgical procedure

Inclusion Criteria at Randomization (following PD1):

  • Documented PD1 according to RANO criteria
  • Eligibility for treatment with lomustine and bevacizumab as medicinal products
  • (ECOG) performance status 0-2
  • Bevacizumab well tolerated and not interrupted for longer than 60 days during first-line treatment
  • Tissue submission among participants for whom operation/re-operation is indicated before second-line treatment starts; operation/re-operation performed >/=28 days after last bevacizumab administration and second-line treatment initiated >/=28 days after surgical wound healed
  • Randomization within 28 days after PD1 among participants for whom operation/re-operation is not necessary
  • First administration of second-line treatment no later than 2 days from randomization

Exclusion criteria

Exclusion Criteria at Enrollment (before PD1):

  • Any prior chemotherapy for glioblastoma and low-grade astrocytomas
  • Any prior radiotherapy to the brain or prior radiotherapy resulting in a potential overlap in the radiation field
  • Prior or current anti-angiogenic treatment
  • Treatment with any other drug within 28 days or 2 investigational agent half-lives (whichever is longer) prior to first study treatment
  • Inadequate hematological, renal, or liver function
  • Inadequately controlled hypertension
  • Prior history of gastrointestinal perforation or abscess
  • cardiovascular disease
  • History or evidence of central nervous system disease unrelated to cancer unless adequately treated with standard medical therapy
  • History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding
  • Serious non-healing wound, active ulcer, or untreated bone fracture
  • Known to any component of bevacizumab/placebo or any of the study drugs
  • Active infection requiring IV antibiotics at start of study treatment
  • Other within 5 years prior to study enrollment, except for carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ treated with curative intent
  • Pregnant or lactating women
  • Participation in any other study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
296 participants (actual)

Study arms

  • Experimental
    First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC

    Participants will receive first-line treatment with radiotherapy, temozolomide, and bevacizumab. All three treatments will be given concurrently for the first 6 weeks, followed by 6 cycles (28 days each) of temozolomide plus bevacizumab, followed by bevacizumab monotherapy until PD1 or unacceptable toxicity. At PD1, participants randomized to bevacizumab will receive bevacizumab plus lomustine until PD2. Following PD2, participants will continue with blinded bevacizumab with the addition of appropriate SOC. Following PD3, for subsequent treatment lines blinded bevacizumab may continue or open-label bevacizumab may be given at the discretion of the investigator and the participant.

    Drug: Bevacizumab · Drug: Lomustine · Radiation: Radiotherapy · Drug: Temozolomide · Drug: SOC Agent

  • Placebo comparator
    First-Line Bevacizumab followed by Placebo + Lomustine/SOC

    Participants will receive first-line treatment with radiotherapy, temozolomide, and bevacizumab. All three treatments will be given concurrently for the first 6 weeks, followed by 6 cycles (28 days each) of temozolomide plus bevacizumab, followed by bevacizumab monotherapy until PD1 or unacceptable toxicity. At PD1, participants randomized to placebo will receive placebo plus lomustine until PD2. Following PD2, participants will continue with blinded placebo with the addition of appropriate SOC. Following PD3, for subsequent treatment lines blinded bevacizumab may continue or open-label bevacizumab may be given at the discretion of the investigator and the participant.

    Drug: Bevacizumab · Drug: Lomustine · Drug: Placebo · Radiation: Radiotherapy · Drug: Temozolomide · Drug: SOC Agent

Interventions

  • Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) intravenous (IV) every 2 weeks (Q2W) throughout the study, with the exception of bevacizumab monotherapy prior to PD1, which will be given as 15 mg/kg IV every 3 weeks (Q3W).

    Also known as: Avastin

  • Lomustine will be administered at a dose of 90 milligrams per square meter (mg/m\^2) orally (PO) every 6 weeks (Q6W), with a cap of 160 milligrams (mg) per dose. In the absence of hematologic toxicity following the first dose, the second and subsequent doses may be increased to 110 mg/m\^2 PO Q6W, with a cap of 200 mg per dose.

  • DrugPlacebo

    Placebo will be administered via IV infusion, in a formulation matched to bevacizumab, Q2W after randomization.

  • RadiationRadiotherapy

    Radiotherapy will be administered for a total dose of 60 Gray (Gy), administered in 2-Gy fractions, 5 days per week for 6 weeks during first-line treatment.

  • Temozolomide will be administered orally (PO) as 75 mg/m\^2 per day for the first 6 weeks of first-line treatment (concurrent treatment), followed by 6 cycles (28 days each) as follows: 150 mg/m\^2 per day for the first 5 days of Cycle 1, then 200 mg/m\^2 per day (if permitted by the participant's hematological and non-hematological toxicity profile) for the first 5 days of Cycles 2-6.

  • DrugSOC Agent

    The choice of SOC agent will be at the discretion of investigator. The SOC agent will be administered during third-line treatment and subsequent lines, as per standard practice.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time frame: From randomization at PD1 until death from any cause or end of study (overall approximately 35 months)

Secondary outcomes

  1. Percentage of Participants Alive at 6, 12, and 18 Months from Randomization

    Time frame: At 6, 12, and 18 months after randomization/PD1 (overall up to approximately 35 months)

  2. Progression-Free Survival (PFS) on 2L Treatment According to Modified Response Assessment in Neuro-Oncology (RANO) Criteria

    Time frame: From first administration of randomized treatment until PD2 or death from any cause (overall approximately 18 months)

  3. PFS on 3L Treatment According to Modified RANO Criteria

    Time frame: From first administration of randomized treatment until PD3 or death from any cause (overall approximately 35 months)

  4. Restricted PFS on 3L Treatment According to Modified RANO Criteria

    Time frame: From first administration of treatment after PD2 until PD3 or death from any cause (overall approximately 26 months)

  5. Percentage of Participants with 2L Objective Response of Complete Response (CR) or Partial Response (PR) According to Modified RANO Criteria

    Time frame: From randomization/PD1 until PD2, death, subsequent anticancer therapy, operation/re-operation for glioblastoma, or 13 weeks after last administration of 2L-treatment, whichever occurs first (approximately 18 months overall)

  6. Percentage of Participants with 3L Objective Response of CR or PR According to Modified RANO Criteria

    Time frame: From PD2 until PD3, death, subsequent anticancer therapy, operation/re-operation for glioblastoma, or 13 weeks after last administration of study treatment, whichever occurs first (approximately 26 months overall)

  7. Percentage of Participants with 2L Disease Control as CR, PR, or Stable Disease According to Modified RANO Criteria

    Time frame: From randomization/PD1 until PD2, death, subsequent anticancer therapy, operation/re-operation for glioblastoma, or 13 weeks after last administration of 2L-treatment, whichever occurs first (approximately 18 months overall)

  8. Percentage of Participants with 3L Disease Control as CR, PR, or SD According to Modified RANO Criteria

    Time frame: From PD2/start of 3L-treatment until PD3, death, subsequent anticancer therapy, operation/re-operation for glioblastoma, or 13 weeks after last administration of 3L-treatment, whichever occurs first (approximately 26 months overall)

  9. Duration of 2L Objective Response Assessed According to Modified RANO Criteria

    Time frame: From first occurrence of CR/PR after randomization/PD1 until PD2, death from any cause, subsequent anticancer therapy, whichever occurs first (approximately 18 months overall)

  10. Duration of 3L Objective Response According to Modified RANO Criteria

    Time frame: From first occurrence of CR/PR after PD2 until PD3, subsequent anticancer therapy, or death from any cause, whichever occurs first (approximately 26 months overall)

  11. Percentage of Participants with Adverse Events (AEs)

    Time frame: From baseline up to 30 days after last dose (up to 41 months overall)

  12. 1L Treatment: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30 (C30) Global Health Status/Global QoL Scale Score

    Time frame: Baseline;Week(Wk)3,5;end of Wk6;Maintenance:Day(D)1 (Visit[V]1), D15 (V2) Cycles(C)1-6 Q4W;Monotherapy:V1-V44 Q3W;Safety Follow-up(FU) (30 days after last 1L dose);PD FUs(8 Wk after Safety FU [PD FU1],then every 12 Wk until PD1) (up to 41 months overall)

  13. 2L and 3L Treatment: Change From 2L Baseline in EORTC QLQ C30 Global Health Status/Global QoL Scale Score

    Time frame: 2L Baseline (2L treatment V1); 2L treatment: V2-V41 (Q2W) until PD2; 3L treatment: V1-V61 (Q2W) until PD3; Safety FU (30 days after last 3L dose); PD FU1 (8 Wk after Safety FU); end of study (up to 41 months overall)

  14. 1L Treatment: Change From Baseline in EORTC QLQ Brain Cancer Module 20 (BN20) Multiple Item Score

    Time frame: Baseline; Wk 3, 5; end of Wk6; Maintenance: D1(V1), D15(V2) of C1-6 (Q4W); Monotherapy: V1-V44 (Q3W); Safety FU (30 days after last 1L dose); PD FUs (8 Wk after Safety FU [PD FU1], then every 12 Wk until PD1) (up to 41 months overall)

  15. 2L and 3L Treatment: Change From 2L Baseline in EORTC QLQ BN20 Multiple Item Score

    Time frame: 2L Baseline (2L treatment V1); 2L treatment: V2-V41 (Q2W) until PD2; 3L treatment: V1-V61 (Q2W) until PD3; Safety FU (30 days after last 3L dose); PD FU1 (8 Wk after Safety FU); end of study (up to 41 months overall)

  16. Percentage of Participants with Mini Mental Status Examination (MMSE) Score <27 or >/=27

    Time frame: Baseline and 2L Baseline

  17. 1L Treatment: Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) z-score

    Time frame: Baseline; Maintenance: D1(V1) Cycles 1, 3, 5 (Q4W); Monotherapy: every 3rd visit starting from V1 to V43 (Q3W); Safety FU (30 days after last 1L dose); PD FUs (8 Wk after Safety FU [PD FU1], then every 12 Wk until PD1) (up to 41 months overall)

  18. 2L and 3L Treatment: Change From 2L Baseline in HVLT-R z-score

    Time frame: 2L Baseline; 2L treatment: every 6th visit starting from V7 to V43 (Q2W); 3L treatment: every 6th visit starting from V1 to V37, V49, V61 (Q2W); Safety FU (30 days after last 3L dose); PD FU1 (8 Wk after Safety FU); end of study (up to 41 months overall)

  19. 1L Treatment: Change From Baseline in Controlled Oral Word Association (COWA) z-score

    Time frame: Baseline; Maintenance: D1(V1) Cycles 1, 3, 5 (Q4W); Monotherapy: every 3rd visit starting from V1 to V43 (Q3W); Safety FU (30 days after last 1L dose); PD FUs (8 Wk after Safety FU [PD FU1], then every 12 Wk until PD1) (up to 41 months overall)

  20. 2L and 3L Treatment: Change From 2L Baseline in COWA z-score

    Time frame: 2L Baseline; 2L treatment: every 6th visit starting from V7 to V43 (Q2W); 3L treatment: every 6th visit starting from V1 to V37, V49, V61 (Q2W); Safety FU (30 days after last 3L dose); PD FU1 (8 Wk after Safety FU); end of study (up to 41 months overall)

  21. 1L Treatment: Change From Baseline in Trail-Making Test (TMT) Part A and B z-score

    Time frame: Baseline; Maintenance: D1(V1) Cycles 1, 3, 5 (Q4W); Monotherapy: every 3rd visit starting from V1 to V43 (Q3W); Safety FU (30 days after last 1L dose); PD FUs (8 Wk after Safety FU [PD FU1], then every 12 Wk until PD1) (up to 41 months overall)

  22. 2L and 3L Treatment: Change From 2L Baseline in TMT Part A and Part B z-score

    Time frame: 2L Baseline; 2L treatment: every 6th visit starting from V7 to V43 (Q2W); 3L treatment: every 6th visit starting from V1 to V37, V49, V61 (Q2W); Safety FU (30 days after last 3L dose); PD FU1 (8 Wk after Safety FU); end of study (up to 41 months overall)

  23. Number of Participants with Hospitalizations According to Type of Hospitalizations

    Time frame: From Baseline up to death or study withdrawal/study end (up to 41 months overall)

  24. Duration of Hospitalizations According to Type of Hospitalizations

    Time frame: From Baseline up to death or study withdrawal/study end (up to 41 months overall)

  25. EuroQol Five-Dimension Questionnaire (EQ-5D) Score

    Time frame: From Baseline up to death or study withdrawal/study end (up to 41 months overall)

07

Study locations

64 sites
  • Medizinische Universität Graz; Universitätsklinik für Neurologie
    Graz, 8036, Austria
  • Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie
    Innsbruck, 6020, Austria
  • Kepler Universitätsklinikum GmbH - Neuromed Campus; Innere Medizin mit Neuroonkologie
    Linz, 4020, Austria
  • Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
    Salzburg, 5020, Austria
  • Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie
    Wien, 1090, Austria
  • Kaiser-Franz-Josef-Spital; Neurologische Abteilung
    Wien, 1100, Austria
  • MBAL Serdika EOOD
    Sofia, 1303, Bulgaria
  • Tom Baker Cancer Centre; Dept of Medicine
    Calgary, Alberta T2N 4N2, Canada
  • McGill University; Montreal Neurological Institute; Oncology
    Montreal, Quebec H3A 2B4, Canada
  • Clinical Hospital Centre Zagreb
    Zagreb, 10000, Croatia
  • Tartu University Hospital; Clinic of Hematology and Oncology
    Tartu, 50406, Estonia
  • HOPITAL JEAN MINJOZ; Oncologie
    Besancon, 25030, France
  • Hopital Avicenne; Neurologie
    Bobigny, 93009, France
  • Hopital Saint Andre; Département de Radiothérapie Et D'Oncologie Médicale
    Bordeaux, 33075, France
  • Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie
    Bron, 69677, France
  • Hopital Cote De Nacre; Unite Neurologie Generale
    Caen, 14033, France
  • Centre Georges Francois Leclerc; Oncologie 3
    Dijon, 21079, France
  • Hopital Roger Salengro; Service de Neurologie
    Lille, 59037, France
  • Hopital de La Timone - CHU de Marseille; Service de neuro-oncologie - Hôpital Adultes - 12ème étage
    Marseille, 13385, France
  • Hôpital Central; Departement de Neuro-Oncologie
    Nancy, 54000, France
  • Hopital Pitié Salpétrière - CHU; Service de neurologie 2 - Mazarin
    Paris, 75651, France
  • Hopital Purpan
    Toulouse Cedex 9, 31059, France
  • Agioi Anargyroi Anticancer Hospital; Radiotherapeutic Clinic
    Kifisia, 14564, Greece
  • Hygeia Hospital
    Marousi, 15123, Greece
  • Papageorgiou General Hospital; Medical Oncology
    Thessaloniki, 546 29, Greece
  • Ospedale Bellaria; U.O. Oncologia Medica
    Bologna, Emilia-Romagna 40133, Italy
  • IFO - Istituto Regina Elena; Oncologia Medica
    Roma, Lazio 00144, Italy
  • Fondazione IRCCS Istituto Neurologico C. Besta; Neuro-oncologia Sperimentale e Terapia Genica
    Milano, Lombardia 20133, Italy
  • Azienda Ospedaliera Le Molintte di Torino; Dipartimento Di Neurologia - Oncologia
    Torino, Piemonte 10126, Italy
  • IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda
    Padova, Veneto 35128, Italy
  • Riga East Clinical University hospital, Clinic Gailezers, Dept of Neurosurgery
    Riga, LV-1038, Latvia
  • IPO de Coimbra; Servico de Oncologia Medica
    Coimbra, 3000-075, Portugal
  • Hospital de Santa Maria; Servico de Oncologia Medica
    Lisboa, 1649-035, Portugal
  • Hospital de Sao Joao; Servico de Oncologia
    Porto, 4200-319, Portugal
  • Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti
    Bucuresti, 022328, Romania
  • Institut Oncologic Ion Chiricuta; Departament Radioterapie
    Cluj-napoca, 400015, Romania
  • Spital Clinic Judetean Mures; Oncologie
    Targu Mures, 540142, Romania
  • Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia
    Badalona, Barcelona 08916, Spain
  • Hospital Universitario Reina Sofia; Servicio de Oncologia
    Córdoba, Cordoba 14004, Spain
  • IInstituto Oncologico de San Sebastian, Oncologikoa; Servicio de Oncologia
    San Sebastian, Guipuzcoa 20014, Spain
  • Hospital Universitario Son Espases; Servicio de Oncologia
    Palma De Mallorca, Islas Baleares 07014, Spain
  • Hospital de Cruces; Servicio de Oncologia
    Bilbao, Vizcaya 48903, Spain
  • Hospital Universitario Infanta Cristina; Servicio de Oncologia
    Badajoz, 06080, Spain
  • Hospital del Mar; Servicio de Oncologia
    Barcelona, 08003, Spain
  • Hospital Duran i Reynals; Oncologia
    Barcelona, 08907, Spain
  • Hospital Ramon y Cajal; Servicio de Oncologia
    Madrid, 28034, Spain
  • Hosp. Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre; Servicio de Oncologia
    Madrid, 28041, Spain
  • Hospital Universitario La Paz; Servicio de Oncologia
    Madrid, 28046, Spain
  • HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia
    Madrid, 28050, Spain
  • Hospital Regional Universitario Carlos Haya; Servicio de Oncologia
    Malaga, 29010, Spain
  • Hospital Clinico Universitario de Salamanca; Servicio de Oncologia
    Salamanca, 37007, Spain
  • Universitetssjukhuset; Onkologkliniken
    Linkoeping, 58185, Sweden
  • Norrlands Universitetssjukhus; Cancer Centrum
    Umea, 901 85, Sweden
  • Akademiska sjukhuset, Onkologkliniken
    Uppsala, 75185, Sweden
  • Adana City Hospital, Medical Oncology
    Adana, 01060, Turkey
  • Baskent Universitesi Tıp Fakultesi; Ic Hastalıkları Anabilim Dalı Tıbbi Onkoloji Bilim Dalı
    Ankara, 06490, Turkey
  • Dokuz Eylul Uni ; Medical Oncology
    Izmir, 35340, Turkey
  • Kocaeli University Faculty of Medicine; Medical oncology
    Izmit, 31380, Turkey
  • Bristol Haematology and Oncology Centre
    Bristol, BS2 8ED, United Kingdom
  • Addenbrookes Hospital; Dept of Oncology
    Cambridge, CB2 2QQ, United Kingdom
  • University College Hospital; Department of Oncology
    London, N7 9NH, United Kingdom
  • Christie Hospital Nhs Trust; Medical Oncology
    Manchester, M2O 4BX, United Kingdom
  • Royal Marsden Hospital; Dept of Medical Oncology
    Sutton, SM2 5PT, United Kingdom
08

References and documents

Publications

  • Brandes AA, Gil-Gil M, Saran F, Carpentier AF, Nowak AK, Mason W, Zagonel V, Dubois F, Finocchiaro G, Fountzilas G, Cernea DM, Chinot O, Anghel R, Ghiringhelli F, Beauchesne P, Lombardi G, Franceschi E, Makrutzki M, Mpofu C, Urban HJ, Pichler J. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. Oncologist. 2019 Apr;24(4):521-528. doi: 10.1634/theoncologist.2018-0290. Epub 2018 Sep 28. PubMed 30266892 ↗
  • Brandes AA, Mason W, Pichler J, Nowak AK, Gil M, Saran F, Revil C, Lutiger B, Carpentier AF. Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy? Future Oncol. 2014 May;10(7):1137-45. doi: 10.2217/fon.14.75. PubMed 24947255 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2013 to primary completion in Jan 2017, 40 months.

Of 51 industry-sponsored phase 2 interventional studies under Glioblastoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 58. This study's 40 months is close to that.

Counting every sponsor, half of 249 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2013
First posted
May 23, 2013
StartActual
Aug 19, 2013
Primary completionActual
Jan 13, 2017
CompletionActual
May 5, 2017
Last update
Apr 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01860638
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 23, 2013
Start date
Aug 19, 2013
Primary completion
Jan 13, 2017
Completion
May 5, 2017
Last update
Apr 30, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Lomustine · Temozolomide

Start the discussion